MPR Weekly Dose

MPR Weekly Dose Podcast #292 — Daridorexant in Pediatric Insomnia; Novel Huntington Disease Tx; vadadustat assessed TIW in anemia CKD; Voceryq accelerated approval; zanubrutinib combo for MCL

12:12

This week, we break down 5 pivotal regulatory decisions. This includes FDA actions for daridorexant in pediatric insomnia and a gene therapy for Huntington disease, alongside an accelerated approval for Voceryq in recurrent respiratory papillomatosis. We also discuss noninferiority data for 3-times-weekly vadadustat in chronic kidney disease anemia and phase 3 findings supporting…